- Home
- SENEA vs ALLO Comparison
SENEA vs ALLO Comparison
Compare SENEA & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SENEA | ALLO |
|---|---|---|
| Founded | 1949 | 2017 |
| Country | United States | United States |
| Employees | 6895 | 152 |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 908.7M | 738.4M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | SENEA | ALLO |
|---|---|---|
| Price | $142.76 | $1.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $8.35 |
| AVG Volume (30 Days) | 80.9K | ★ 6.9M |
| Earning Date | 06-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $142,416.42 |
| P/E Ratio | $13.21 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $87.99 | $0.99 |
| 52 Week High | $167.52 | $4.46 |
Technical Indicators
Market Signals| Indicator | SENEA | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 52.57 | 37.17 |
| Support Level | $138.19 | $1.85 |
| Resistance Level | $148.36 | $2.71 |
| Average True Range (ATR) | 5.56 | 0.14 |
| MACD | 0.40 | -0.02 |
| Stochastic Oscillator | 66.95 | 11.22 |
Price Performance
Historical ComparisonAbout SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).